Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
Globe Newswire•06/11/2026•12:00 ET
0
Key Highlights
- ➤Two-year overall survival reached 70% in first-line combination patients
- ➤Combination delivered 29% response rate and 24.1-month median response duration
- ➤Median overall survival was not reached after 29-month median follow-up
- ➤Immunocore plans randomized Phase 2/3 DUET-UVEAL trial
- ➤Combination produced 71% disease control rate and 8.1-month median progression-free survival
Expert Statements
Omid Hamid, Chief of Research & Immuno-Oncology and Co-Director, Cutaneous Malignancy Program at The Angeles Clinic & Research Institute
“Immunocore continues to lead bispecific T cell engager innovation, having demonstrated the first overall survival benefit in metastatic uveal melanoma. We are now seeing the synergistic potential of combining two clinically active ImmTAC therapies. The 1- and 2-year overall survival data could be practice-changing, and I look forward to evaluating this combination in a randomized trial for patients with metastatic uveal melanoma.”
Mohammed Dar, Executive Vice President, Clinical Development and Chief Medical Officer of Immunocore
“These encouraging Phase 1 data suggest combining brenetafusp with tebentafusp may offer a meaningful new option for HLA-A*02:01-positive patients with metastatic uveal melanoma.”
Mohammed Dar, Executive Vice President, Clinical Development and Chief Medical Officer of Immunocore
“Building on our leadership with KIMMTRAK, we believe that targeting both gp100 and PRAME – a combined ImmTAC approach – offers the potential to deliver an even greater benefit for HLA-A*02:01-positive patients.”
In 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remained on study
Majority of patients (64%) with an OS over 2 years received only the combination
Get started
Create a free account to read the full story.